Literature DB >> 23729680

STAT5 and prolactin participate in a positive autocrine feedback loop that promotes angiogenesis.

Xinhai Yang1, Kristy Meyer1, Andreas Friedl2.   

Abstract

We have shown previously that the murine prolactin/growth hormone family member proliferin plays a pivotal role in angiogenesis induced by the FGF2/STAT5 signaling cascade. To delineate the signaling pathway downstream of STAT5 in the human system, where proliferin does not exist, we expressed constitutively active (CA) or dominant-negative (DN) mutant STAT5A in hCMEC/D3 human brain endothelial cells. We found that conditioned medium from CA-STAT5A- but not from DN-STAT5A-overexpressing endothelial cells (EC) is sufficient to induce EC migration and tube formation but not proliferation, indicating that STAT5A regulates the secretion of autocrine proangiogenic factors. We identified prolactin (PRL) as a candidate autocrine factor. CA-STAT5A expression stimulates PRL production at the RNA and protein level, and STAT5A binds to the PRL promoter region, suggesting direct transcriptional regulation. Medium conditioned by CA-STAT5A-overexpressing EC induces phosphorylation of the PRL receptor and activates MAPK. Knockdown of PRL expression by shRNA or blocking of PRL activity with neutralizing antibodies removed the CA-STAT5A-dependent proangiogenic activity from the conditioned medium of EC. The addition of recombinant PRL restores this activity. STAT5A-induced PRL in the conditioned medium can activate STAT5, STAT1, and to a lesser extent STAT3 in hCMEC/D3 cells, suggesting the existence of a positive feedback loop between STAT5 and PRL that promotes angiogenesis. Furthermore, we find that VEGF, a potent proangiogenic factor, is induced by activation of STAT5A, and VEGF induction depends on PRL expression. These observations demonstrate a STAT5/PRL/VEGF signaling cascade in human brain EC and implicate PRL and VEGF as autocrine regulators of EC migration, invasion, and tube formation.

Entities:  

Keywords:  Angiogenesis; Autocrine Factors; Cell Migration; Cell Signaling; Prolactin; STAT Transcription Factor; STAT5

Mesh:

Substances:

Year:  2013        PMID: 23729680      PMCID: PMC3774384          DOI: 10.1074/jbc.M113.481119

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  64 in total

1.  Dual inhibition of Jak2 and STAT5 enhances killing of myeloproliferative neoplasia cells.

Authors:  M Bar-Natan; E A Nelson; S R Walker; Y Kuang; R J Distel; D A Frank
Journal:  Leukemia       Date:  2011-12-02       Impact factor: 11.528

2.  Overexpression of vascular endothelial growth factor164 and its co-receptor neuropilin-1 in estrogen-induced rat pituitary tumors and GH3 rat pituitary tumor cells.

Authors:  S K Banerjee; M N Zoubine; T M Tran; A P Weston; D R Campbell
Journal:  Int J Oncol       Date:  2000-02       Impact factor: 5.650

3.  Transcriptional regulation of vascular endothelial growth factor expression in epithelial and stromal cells during mouse mammary gland development.

Authors:  R C Hovey; A S Goldhar; J Baffi; B K Vonderhaar
Journal:  Mol Endocrinol       Date:  2001-05

4.  Regulation of vascular endothelial growth factor (VEGF) gene transcription by estrogen receptors alpha and beta.

Authors:  M D Mueller; J L Vigne; A Minchenko; D I Lebovic; D C Leitman; R N Taylor
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

5.  Structural and functional effects of high prolactin levels on injured endothelial cells: evidence for an endothelial prolactin receptor.

Authors:  C J Merkle; L A Schuler; R C Schaeffer; J M Gribbon; D W Montgomery
Journal:  Endocrine       Date:  2000-08       Impact factor: 3.633

6.  Angiogenesis induced by signal transducer and activator of transcription 5A (STAT5A) is dependent on autocrine activity of proliferin.

Authors:  Xinhai Yang; Dianhua Qiao; Kristy Meyer; Thomas Pier; Sunduz Keles; Andreas Friedl
Journal:  J Biol Chem       Date:  2011-12-23       Impact factor: 5.157

7.  Human umbilical vein endothelial cells express multiple prolactin isoforms.

Authors:  A M Corbacho; Y Macotela; G Nava; L Torner; Z Dueñas; G Noris; M A Morales; G Martínez De La Escalera; C Clapp
Journal:  J Endocrinol       Date:  2000-07       Impact factor: 4.286

8.  Expression of prolactin gene and secretion of prolactin by rat retinal capillary endothelial cells.

Authors:  A Ochoa; P Montes de Oca; J C Rivera; Z Dueñas; G Nava; G M de La Escalera; C Clapp
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-06       Impact factor: 4.799

9.  Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and soluble interleukin-2 receptor (sIL-2R) concentrations in peripheral blood as markers of pituitary tumours.

Authors:  J Komorowski; J Jankewicz; H Stepień
Journal:  Cytobios       Date:  2000

10.  Functional consequences of prolactin signalling in endothelial cells: a potential link with angiogenesis in pathophysiology?

Authors:  Anne Q Reuwer; Patrycja Nowak-Sliwinska; Laurie A Mans; Chris M van der Loos; Jan H von der Thüsen; Marcel Th B Twickler; C Arnold Spek; Vincent Goffin; Arjan W Griffioen; Keren S Borensztajn
Journal:  J Cell Mol Med       Date:  2012-09       Impact factor: 5.310

View more
  20 in total

Review 1.  Role of pregnancy hormones and hormonal interaction on the maternal cardiovascular system: a literature review.

Authors:  Vitaris Kodogo; Feriel Azibani; Karen Sliwa
Journal:  Clin Res Cardiol       Date:  2019-02-26       Impact factor: 5.460

2.  GDM alters paracrine regulation of feto-placental angiogenesis via the trophoblast.

Authors:  Jelena Loegl; Erika Nussbaumer; Silvija Cvitic; Berthold Huppertz; Gernot Desoye; Ursula Hiden
Journal:  Lab Invest       Date:  2017-01-23       Impact factor: 5.662

Review 3.  Minireview: Extrapituitary prolactin: an update on the distribution, regulation, and functions.

Authors:  Robert J Marano; Nira Ben-Jonathan
Journal:  Mol Endocrinol       Date:  2014-04-02

4.  Modeling prolactin actions in breast cancer in vivo: insights from the NRL-PRL mouse.

Authors:  Kathleen A O'Leary; Michael P Shea; Linda A Schuler
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

Review 5.  Prolactin: The Third Hormone in Breast Cancer.

Authors:  Linda A Schuler; Kathleen A O'Leary
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-16       Impact factor: 6.055

6.  Low Prolactin and High 20-α-Hydroxysteroid Dehydrogenase Levels Contribute to Lower Progesterone Levels in HIV-Infected Pregnant Women Exposed to Protease Inhibitor-Based Combination Antiretroviral Therapy.

Authors:  Eszter Papp; Kayode Balogun; Nicole Banko; Hakimeh Mohammadi; Mona Loutfy; Mark H Yudin; Rajiv Shah; Jay MacGillivray; Kellie E Murphy; Sharon L Walmsley; Michael Silverman; Lena Serghides
Journal:  J Infect Dis       Date:  2016-01-05       Impact factor: 5.226

Review 7.  The role of the prolactin/vasoinhibin axis in rheumatoid arthritis: an integrative overview.

Authors:  Carmen Clapp; Norma Adán; María G Ledesma-Colunga; Mariana Solís-Gutiérrez; Jakob Triebel; Gonzalo Martínez de la Escalera
Journal:  Cell Mol Life Sci       Date:  2016-03-29       Impact factor: 9.261

8.  Meningeal CGRP-Prolactin Interaction Evokes Female-Specific Migraine Behavior.

Authors:  Amanda Avona; Bianca N Mason; Carolina Burgos-Vega; Anahit H Hovhannisyan; Sergei N Belugin; Jennifer Mecklenburg; Vincent Goffin; Naureen Wajahat; Theodore J Price; Armen N Akopian; Gregory Dussor
Journal:  Ann Neurol       Date:  2021-04-22       Impact factor: 11.274

9.  MiR-211/STAT5A Signaling Modulates Migration of Mesenchymal Stem Cells to Improve its Therapeutic Efficacy.

Authors:  Xinyang Hu; Panpan Chen; Yan Wu; Kan Wang; Yinchuan Xu; Han Chen; Ling Zhang; Rongrong Wu; Keith A Webster; Hong Yu; Wei Zhu; Jian'an Wang
Journal:  Stem Cells       Date:  2016-05-19       Impact factor: 6.277

Review 10.  Human miR-221/222 in Physiological and Atherosclerotic Vascular Remodeling.

Authors:  Dmitry A Chistiakov; Igor A Sobenin; Alexander N Orekhov; Yuri V Bobryshev
Journal:  Biomed Res Int       Date:  2015-06-29       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.